Positive results from a clinical study into biotech company, AELIX’ Therapeutics’, HIV vaccine have been published in Nature Medicine journal.
The announcement came today (November 2) from the Spanish-based company that specializes in developing immunotherapies for HIV infection.
Christian Brander, co-founder and chief scientific officer at AELIX, said: “We are excited to have published the data on this important study in such a prestigious journal, reaching a wide readership. Our T-cell vaccine approach has the potential to play a critical role in strategies to cure HIV infection. AELIX is a leader in developing vaccine-based solutions for an HIV cure.”
Positive data published
The AELIX-002 study was conducted in collaboration with Gilead Sciences at the IrsiCaixa AIDS Research Institute, a center jointly promoted by the ‘la Caixa’ Foundation and the Department of Health of the Generalitat de Catalunya. It evaluated the safety, tolerability, immunogenicity and efficacy of AELIX’ HTI T-cell therapeutic HIV vaccine in early treated people living with HIV. The study achieved its primary and secondary endpoints of safety, tolerability and immunogenicity.
The trial also evaluated the efficacy of the vaccination and showed that the use of the AELIX HTI vaccine can enable a prolonged period without AntiRetroviral Therapy (ART). The strength of the vaccine-induced T-cell response significantly correlated with prolonged periods off ART. The results support the development of combination strategies based on the HTI vaccine to control HIV without the need for ongoing ART.
Principal investigator, Beatriz Mothe, said: “The positive results from this trial show that it is possible to induce an immune response in a person living with HIV which enables them to improve the suppression of the virus in the absence of antiretroviral medication.”
“A safe and effective HTI vaccine could become the backbone of combination strategies to achieve complete viral suppression, which ultimately is our common goal.”
A second clinical study, AELIX-003, is being conducted in collaboration with Gilead. This active phase 2 study is designed to evaluate the HTI vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7) agonist, vesatolimod, in people with HIV on antiretroviral therapy.
Vesatolimod is an immune modulator being evaluated as part of an investigational combination regimen that could potentially lead to viral remission. In this study, vesatolimod is expected to enhance the vaccine-induced immune response leading to the elimination of virus-infected cells.
Complex scientific challenge
Devi SenGupta, executive director, HIV clinical development at Gilead Sciences, said: “Illuminating the pathways to an HIV cure is an incredibly complex scientific challenge and collaboration is key to catalysing the research.
“The AELIX-003 study aims to build upon these positive results published in Nature Medicine and may help inform future directions for HIV cure research. We look forward to presenting the findings from this phase 2 study at a future HIV congress.”
The HIV epidemic affects a projected 38.4 million people worldwide, with 650,000 deaths and 1.5 million new infections in 2021. Globally, it is estimated that 28.7 million people are currently accessing antiretroviral therapy. Early detection of HIV, as well as new innovations, like the AELIX T-cell vaccine, leading to a prolonged period without ART, could be a game changer in HIV cure strategies as a combination approach to treating the disease.